Symbols / BLLN Stock $77.25 -5.52% BillionToOne, Inc.

Healthcare • Diagnostics & Research • United States • NMS
BLLN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Dr. Oguzhan Atay Ph.D.
Exch · Country NMS · United States
Market Cap 3.55B
Enterprise Value 3.37B
Income 2.92M
Sales 305.11M
FCF (ttm) 20.81M
Book/sh 10.48
Cash/sh 10.79
Employees 713
Insider 10d —
IPO Nov 06, 2025
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 551.79
Forward P/E 86.31
PEG —
P/S 11.65
P/B 7.37
P/C —
EV/EBITDA 147.00
EV/Sales 11.05
Quick Ratio 11.21
Current Ratio 11.69
Debt/Eq 22.68
LT Debt/Eq —
EPS (ttm) 0.14
EPS next Y 0.90
EPS Growth —
Revenue Growth 113.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-03-04
ROA 2.14%
ROE 2.30%
ROIC —
Gross Margin 68.32%
Oper. Margin 10.76%
Profit Margin 0.96%
Shs Outstand 41.44M
Shs Float 23.16M
Insider Own 46.74%
Instit Own 36.02%
Short Float 7.78%
Short Ratio 5.79
Short Interest 1.94M
52W High 138.70
vs 52W High -44.30%
52W Low 61.96
vs 52W Low 24.68%
Beta —
Impl. Vol. 1.09%
Rel Volume 0.80
Avg Volume 324.96K
Volume 260.30K
Target (mean) $116.71
Tgt Median $120.00
Tgt Low $90.00
Tgt High $145.00
# Analysts 7
Recom Buy
Prev Close $81.76
Price $77.25
Change -5.52%
About

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$116.71
Mean price target
2. Current target
$77.25
Latest analyst target
3. DCF / Fair value
$9.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$77.25
Low
$90.00
High
$145.00
Mean
$116.71

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-30 main Guggenheim Buy → Buy $100
2026-03-05 main Wells Fargo Equal-Weight → Equal-Weight $90
2026-03-05 reit Guggenheim Buy → Buy $120
2026-03-05 main BTIG Buy → Buy $140
2025-12-10 main JP Morgan Overweight → Overweight $145
2025-12-10 reit BTIG Buy → Buy $160
2025-12-01 init Piper Sandler — → Overweight $150
2025-12-01 init Stifel — → Buy $145
2025-12-01 init Wells Fargo — → Equal-Weight $110
2025-12-01 init JP Morgan — → Overweight $150
2025-12-01 init Jefferies — → Hold $117
2025-12-01 init BTIG — → Buy $160
News
RSS: Latest BLLN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-31 PAGANO ANTHONY Director — 4,896 $0.00 $0
2025-11-07 KOLLURI KRISHNA KITTU Director and Beneficial Owner of more than 10% of a Class of Security — 4,239,506 — —
2025-11-07 LYNCH THOMAS P General Counsel — 100 $100.03 $10,003
2025-11-07 NEOTRIBE VENTURES I L.P. Beneficial Owner of more than 10% of a Class of Security — 4,239,506 — —
2025-11-07 JOHNSON NANCY JOANN Officer — 6,900 $100.03 $690,207
2025-11-07 TEN BOSCH JOHN RODERICK PH.D. Officer — 800 $100.03 $80,024
2025-11-07 BREMNER THOMAS S. Director — 41,666 $100.03 $4,167,850
2025-11-07 BREMNER THOMAS S. Director — 1,947,272 — —
2025-11-07 RAI AKSHAY Director — 1,787,090 — —
2025-11-07 RAI AKSHAY Director — 2,500 $100.03 $250,075
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31
Total Revenue
305.11
Operating Revenue
305.11
Cost Of Revenue
96.65
Reconciled Cost Of Revenue
96.65
Gross Profit
208.46
Operating Expense
192.44
Research And Development
49.38
Selling General And Administration
143.05
Total Expenses
289.09
Operating Income
16.02
Total Operating Income As Reported
16.02
EBITDA
19.76
Normalized EBITDA
19.76
Reconciled Depreciation
11.91
EBIT
7.85
Total Unusual Items
0.00
Total Unusual Items Excluding Goodwill
0.00
Special Income Charges
0.00
Net Income
7.45
Pretax Income
7.76
Net Non Operating Interest Income Expense
7.66
Interest Expense Non Operating
0.10
Net Interest Income
7.66
Interest Expense
0.10
Interest Income Non Operating
7.75
Interest Income
7.75
Other Income Expense
-15.92
Other Non Operating Income Expenses
-15.92
Tax Provision
0.30
Tax Rate For Calcs
0.00
Tax Effect Of Unusual Items
0.00
Net Income Including Noncontrolling Interests
7.45
Net Income From Continuing Operation Net Minority Interest
7.45
Net Income From Continuing And Discontinued Operation
7.45
Net Income Continuous Operations
7.45
Normalized Income
7.45
Net Income Common Stockholders
2.92
Otherunder Preferred Stock Dividend
4.54
Diluted EPS
—
Basic EPS
—
Basic Average Shares
—
Diluted Average Shares
—
Diluted NI Availto Com Stockholders
2.92
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
632.65
—
—
Current Assets
560.56
—
—
Cash Cash Equivalents And Short Term Investments
495.98
—
—
Cash And Cash Equivalents
495.98
—
—
Receivables
41.62
—
—
Accounts Receivable
41.62
—
—
Inventory
17.55
—
—
Other Current Assets
5.42
—
—
Total Non Current Assets
72.10
—
—
Net PPE
66.52
-3.07%
68.62
—
Gross PPE
89.78
—
—
Accumulated Depreciation
-23.27
-35.66%
-17.15
—
Properties
0.00
—
—
Machinery Furniture Equipment
35.35
—
—
Construction In Progress
2.22
—
—
Other Properties
51.71
—
—
Leases
0.49
—
—
Goodwill And Other Intangible Assets
0.59
+158.59%
0.23
—
Other Intangible Assets
0.59
+158.59%
0.23
—
Other Non Current Assets
4.99
—
—
Total Liabilities Net Minority Interest
152.55
—
—
Current Liabilities
47.96
—
—
Payables And Accrued Expenses
17.71
+66.01%
10.67
—
Payables
7.37
—
—
Accounts Payable
7.18
—
—
Current Accrued Expenses
10.34
+74.59%
5.92
—
Pensionand Other Post Retirement Benefit Plans Current
12.55
—
—
Total Tax Payable
0.19
—
—
Current Debt And Capital Lease Obligation
5.60
—
—
Current Capital Lease Obligation
5.60
—
—
Current Deferred Liabilities
2.19
—
—
Current Deferred Revenue
2.19
—
—
Other Current Liabilities
9.91
+3556.83%
0.27
—
Total Non Current Liabilities Net Minority Interest
104.59
—
—
Long Term Debt And Capital Lease Obligation
103.30
—
—
Long Term Debt
57.23
—
—
Long Term Capital Lease Obligation
46.07
—
—
Non Current Deferred Liabilities
1.29
0.00
—
Non Current Deferred Revenue
1.29
0.00
—
Preferred Securities Outside Stock Equity
0.00
—
—
Stockholders Equity
480.11
—
—
Common Stock Equity
480.11
—
—
Capital Stock
0.00
—
—
Common Stock
0.00
—
—
Share Issued
45.80
+2.42%
44.72
+0.00%
44.72
Ordinary Shares Number
45.80
+2.42%
44.72
+0.00%
44.72
Additional Paid In Capital
756.64
—
—
Retained Earnings
-274.75
—
—
Gains Losses Not Affecting Retained Earnings
-1.79
0.00
—
Other Equity Adjustments
-1.79
—
—
Total Equity Gross Minority Interest
480.11
—
—
Total Capitalization
537.33
—
—
Working Capital
512.60
—
—
Invested Capital
537.33
—
—
Total Debt
108.89
—
—
Capital Lease Obligations
51.67
—
—
Net Tangible Assets
479.52
+290.37%
-251.88
—
Tangible Book Value
479.52
+290.37%
-251.88
—
Line Item Trend 2025-12-31
Operating Cash Flow
24.59
Cash Flow From Continuing Operating Activities
24.59
Net Income From Continuing Operations
7.45
Depreciation Amortization Depletion
11.91
Depreciation
11.91
Depreciation And Amortization
11.91
Other Non Cash Items
3.95
Stock Based Compensation
15.91
Operating Gains Losses
7.42
Gain Loss On Investment Securities
7.36
Gain Loss On Sale Of PPE
0.06
Change In Working Capital
-22.05
Change In Receivables
-16.91
Changes In Account Receivables
-16.91
Change In Inventory
-8.81
Change In Prepaid Assets
-2.19
Change In Payables And Accrued Expense
9.64
Change In Accrued Expense
7.87
Change In Payable
1.77
Change In Account Payable
1.77
Change In Other Working Capital
0.67
Change In Other Current Assets
-0.06
Change In Other Current Liabilities
-4.39
Investing Cash Flow
-8.92
Cash Flow From Continuing Investing Activities
-8.92
Net PPE Purchase And Sale
-8.88
Purchase Of PPE
-8.88
Capital Expenditure
-8.92
Net Investment Purchase And Sale
0.00
Sale Of Investment
0.00
Net Intangibles Purchase And Sale
-0.04
Purchase Of Intangibles
-0.04
Financing Cash Flow
288.82
Cash Flow From Continuing Financing Activities
288.82
Net Issuance Payments Of Debt
-1.73
Issuance Of Debt
0.05
Repayment Of Debt
-1.78
Long Term Debt Issuance
0.05
Long Term Debt Payments
-1.78
Net Long Term Debt Issuance
-1.73
Net Common Stock Issuance
292.04
Common Stock Payments
0.00
Repurchase Of Capital Stock
0.00
Proceeds From Stock Option Exercised
3.12
Net Other Financing Charges
-4.61
Changes In Cash
304.50
Beginning Cash Position
191.48
End Cash Position
495.98
Free Cash Flow
15.67
Interest Paid Supplemental Data
4.65
Income Tax Paid Supplemental Data
0.49
Common Stock Issuance
292.04
Issuance Of Capital Stock
292.04
Net Preferred Stock Issuance
0.00
Preferred Stock Issuance
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category